Improved survival with ipilimumab in patients with metastatic melanoma.: [Erratum appears in N Engl J Med. 2010 Sep 23;363(13):1290]

F S Hodi; S J O'Day; D F McDermott; R W Weber; J A Sosman; J B Haanen; R Gonzalez; C Robert; D Schadendorf; J C Hassel; W Akerley; A J van den Eertwegh; J Lutzky; P Lorigan; J M Vaubel; G P Linette; D Hogg; C H Ottensmeier; C Lebbe; C Peschel; I Quirt; J I Clark; J D Wolchok; J S Weber; J Tian; M J Yellin; G M Nichol; A Hoos; W J Urba

Improved survival with ipilimumab in patients with metastatic melanoma. [Erratum appears in N Engl J Med. 2010 Sep 23;363(13):1290]

F S Hodi, S J O'Day, D F McDermott, R W Weber, J A Sosman, J B Haanen, R Gonzalez, C Robert, D Schadendorf, J C Hassel, W Akerley, A J van den Eertwegh, J Lutzky, P Lorigan, J M Vaubel, G P Linette, D Hogg, C H Ottensmeier, C Lebbe, C PeschelI Quirt, J I Clark, J D Wolchok, J S Weber, J Tian, M J Yellin, G M Nichol, A Hoos, W J Urba

ALC Administration general

Research output: Contribution to journal › Article › peer-review

Abstract

BACKGROUND: An improvement in overall survival among patients with metastatic melanoma has been an elusive goal. In this phase 3 study, ipilimumab--which blocks cytotoxic T-lymphocyte-associated antigen 4 to potentiate an antitumor T-cell response--administered with or without a glycoprotein 100 (gp100) peptide vaccine was compared with gp100 alone in patients with previously treated metastatic melanoma. METHODS: A total of 676 HLA-A*0201-positive patients with unresectable stage III or IV melanoma, whose disease had progressed while they were receiving therapy for metastatic disease, were randomly assigned, in a 3:1:1 ratio, to receive ipilimumab plus gp100 (403 patients), ipilimumab alone (137), or gp100 alone (136). Ipilimumab, at a dose of 3 mg per kilogram of body weight, was administered with or without gp100 every 3 weeks for up to four treatments (induction). Eligible patients could receive reinduction therapy. The primary end point was overall survival. RESULTS: The median overall survival was 10.0 months among patients receiving ipilimumab plus gp100, as compared with 6.4 months among patients receiving gp100 alone (hazard ratio for death, 0.68; P

Original language	English
Pages (from-to)	711-723
Number of pages	13
Journal	New England Journal Of Medicine
Volume	363
Issue number	8 PG - 711-23
Publication status	Published - 2010

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., Akerley, W., van den Eertwegh, A. J., Lutzky, J., Lorigan, P., Vaubel, J. M., Linette, G. P., Hogg, D., Ottensmeier, C. H., Lebbe, C., ... Urba, W. J. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. [Erratum appears in N Engl J Med. 2010 Sep 23;363(13):1290]. New England Journal Of Medicine, 363(8 PG - 711-23), 711-723.

@article{55b767022aa946d8836cb6eefbe84b62,

title = "Improved survival with ipilimumab in patients with metastatic melanoma.: [Erratum appears in N Engl J Med. 2010 Sep 23;363(13):1290]",

abstract = "BACKGROUND: An improvement in overall survival among patients with metastatic melanoma has been an elusive goal. In this phase 3 study, ipilimumab--which blocks cytotoxic T-lymphocyte-associated antigen 4 to potentiate an antitumor T-cell response--administered with or without a glycoprotein 100 (gp100) peptide vaccine was compared with gp100 alone in patients with previously treated metastatic melanoma. METHODS: A total of 676 HLA-A*0201-positive patients with unresectable stage III or IV melanoma, whose disease had progressed while they were receiving therapy for metastatic disease, were randomly assigned, in a 3:1:1 ratio, to receive ipilimumab plus gp100 (403 patients), ipilimumab alone (137), or gp100 alone (136). Ipilimumab, at a dose of 3 mg per kilogram of body weight, was administered with or without gp100 every 3 weeks for up to four treatments (induction). Eligible patients could receive reinduction therapy. The primary end point was overall survival. RESULTS: The median overall survival was 10.0 months among patients receiving ipilimumab plus gp100, as compared with 6.4 months among patients receiving gp100 alone (hazard ratio for death, 0.68; P",

author = "Hodi, {F S} and O'Day, {S J} and McDermott, {D F} and Weber, {R W} and Sosman, {J A} and Haanen, {J B} and R Gonzalez and C Robert and D Schadendorf and Hassel, {J C} and W Akerley and {van den Eertwegh}, {A J} and J Lutzky and P Lorigan and Vaubel, {J M} and Linette, {G P} and D Hogg and Ottensmeier, {C H} and C Lebbe and C Peschel and I Quirt and Clark, {J I} and Wolchok, {J D} and Weber, {J S} and J Tian and Yellin, {M J} and Nichol, {G M} and A Hoos and Urba, {W J}",

year = "2010",

language = "English",

volume = "363",

pages = "711--723",

journal = "New England Journal Of Medicine",

issn = "1533-4406",

publisher = "Massachussetts Medical Society",

number = "8 PG - 711-23",

}

Hodi, FS, O'Day, SJ, McDermott, DF, Weber, RW, Sosman, JA, Haanen, JB, Gonzalez, R, Robert, C, Schadendorf, D, Hassel, JC, Akerley, W, van den Eertwegh, AJ, Lutzky, J, Lorigan, P, Vaubel, JM, Linette, GP, Hogg, D, Ottensmeier, CH, Lebbe, C, Peschel, C, Quirt, I, Clark, JI, Wolchok, JD, Weber, JS, Tian, J, Yellin, MJ, Nichol, GM, Hoos, A & Urba, WJ 2010, 'Improved survival with ipilimumab in patients with metastatic melanoma. [Erratum appears in N Engl J Med. 2010 Sep 23;363(13):1290]', New England Journal Of Medicine, vol. 363, no. 8 PG - 711-23, pp. 711-723.

TY - JOUR

T1 - Improved survival with ipilimumab in patients with metastatic melanoma.

T2 - [Erratum appears in N Engl J Med. 2010 Sep 23;363(13):1290]

AU - Hodi, F S

AU - O'Day, S J

AU - McDermott, D F

AU - Weber, R W

AU - Sosman, J A

AU - Haanen, J B

AU - Gonzalez, R

AU - Robert, C

AU - Schadendorf, D

AU - Hassel, J C

AU - Akerley, W

AU - van den Eertwegh, A J

AU - Lutzky, J

AU - Lorigan, P

AU - Vaubel, J M

AU - Linette, G P

AU - Hogg, D

AU - Ottensmeier, C H

AU - Lebbe, C

AU - Peschel, C

AU - Quirt, I

AU - Clark, J I

AU - Wolchok, J D

AU - Weber, J S

AU - Tian, J

AU - Yellin, M J

AU - Nichol, G M

AU - Hoos, A

AU - Urba, W J

PY - 2010

Y1 - 2010

N2 - BACKGROUND: An improvement in overall survival among patients with metastatic melanoma has been an elusive goal. In this phase 3 study, ipilimumab--which blocks cytotoxic T-lymphocyte-associated antigen 4 to potentiate an antitumor T-cell response--administered with or without a glycoprotein 100 (gp100) peptide vaccine was compared with gp100 alone in patients with previously treated metastatic melanoma. METHODS: A total of 676 HLA-A*0201-positive patients with unresectable stage III or IV melanoma, whose disease had progressed while they were receiving therapy for metastatic disease, were randomly assigned, in a 3:1:1 ratio, to receive ipilimumab plus gp100 (403 patients), ipilimumab alone (137), or gp100 alone (136). Ipilimumab, at a dose of 3 mg per kilogram of body weight, was administered with or without gp100 every 3 weeks for up to four treatments (induction). Eligible patients could receive reinduction therapy. The primary end point was overall survival. RESULTS: The median overall survival was 10.0 months among patients receiving ipilimumab plus gp100, as compared with 6.4 months among patients receiving gp100 alone (hazard ratio for death, 0.68; P

AB - BACKGROUND: An improvement in overall survival among patients with metastatic melanoma has been an elusive goal. In this phase 3 study, ipilimumab--which blocks cytotoxic T-lymphocyte-associated antigen 4 to potentiate an antitumor T-cell response--administered with or without a glycoprotein 100 (gp100) peptide vaccine was compared with gp100 alone in patients with previously treated metastatic melanoma. METHODS: A total of 676 HLA-A*0201-positive patients with unresectable stage III or IV melanoma, whose disease had progressed while they were receiving therapy for metastatic disease, were randomly assigned, in a 3:1:1 ratio, to receive ipilimumab plus gp100 (403 patients), ipilimumab alone (137), or gp100 alone (136). Ipilimumab, at a dose of 3 mg per kilogram of body weight, was administered with or without gp100 every 3 weeks for up to four treatments (induction). Eligible patients could receive reinduction therapy. The primary end point was overall survival. RESULTS: The median overall survival was 10.0 months among patients receiving ipilimumab plus gp100, as compared with 6.4 months among patients receiving gp100 alone (hazard ratio for death, 0.68; P

UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medc&AN=20525992 NS -

UR - http://www.mendeley.com/research/improved-survival-ipilimumab-patients-metastatic-melanomaerratum-appears-n-engl-j-med-2010-sep-23363

M3 - Article

SN - 1533-4406

VL - 363

SP - 711

EP - 723

JO - New England Journal Of Medicine

JF - New England Journal Of Medicine

IS - 8 PG - 711-23

ER -

Improved survival with ipilimumab in patients with metastatic melanoma. [Erratum appears in N Engl J Med. 2010 Sep 23;363(13):1290]

Abstract

UN SDGs

Other files and links

Fingerprint

Cite this